Compare A O Smith Corp (AOS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
A O Smith Corp vs Gilead Sciences, Inc. — how do they compare? A O Smith Corp trades at $61 (market cap $8.33B), while Gilead Sciences, Inc. trades at $130.62 (market cap $161.19B). The key difference: Gilead Sciences, Inc. is far larger — about 19.4× A O Smith Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.53%). Which is the better fit depends on your goals.
| AOS | GILD | |
|---|---|---|
Market Cap | $8.33B | $161.19B |
Sector | Industrials | Health |
52-Week High | $80.47 | $155.80 |
52-Week Low | $55.78 | $108.22 |
Enterprise Value | $8.78B | $175.72B |
Dividend Yield | 2.35% | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
A.O. Smith (AOS) trades at $60.44, up 2.41% today, with a bearish technical signal despite recent leadership changes. The company reported mixed Q1 2026 earnings, missing EPS estimates at $0.85 versus $0.94 expected, while maintaining solid profitability with a 13.84% net margin. Cash flow trends show improving operations, and the stock offers a dividend with a recent $0.36 payout announced.
The outlook is cautious due to earnings volatility and bearish technicals, but valuation appears reasonable with a P/E of 16.12. Risks include China market weakness and competitive pressures, while analyst consensus leans hold with a $68 price target suggesting modest upside potential from current levels.
Gilead Sciences (GILD) trades at $129.83, down 3.72% on the day, with a bullish technical signal and strong fundamentals including a 30.99% net income margin and 43.19% ROE. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer expand its oncology portfolio, while earnings have consistently beaten estimates in recent quarters. The stock shows robust profitability and cash flow generation despite a net cash outflow in 2025.
Outlook remains positive with a consensus price target of $154.57 (19% upside), supported by analyst bullishness (67% buy ratings) and growth catalysts in HIV and oncology. Key risks include patent expirations for key drugs and competitive pressures in the biotech sector. The valuation at 17.66x P/E appears reasonable given earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
